<DOC>
	<DOCNO>NCT02378142</DOCNO>
	<brief_summary>The purpose study test good bad effect study drug pazopanib .</brief_summary>
	<brief_title>Pazopanib Treating Uterine Leiomyosarcoma</brief_title>
	<detailed_description />
	<mesh_term>Leiomyosarcoma</mesh_term>
	<criteria>Recurrent persistent leiomyosarcoma uterus . measurable disease . Patients must least one `` target lesion '' use assess response protocol define RECIST version 1.1 ( Section 8.1 ) . Patients must eligible high priority GOG protocol , one exist . In general , would refer active GOG Phase III protocol . GOG Performance Status 0 , 1 , 2 . Patients free active infection require antibiotic ( exception uncomplicated UTI ) . Any hormonal therapy direct malignant tumor must discontinue least one week prior registration . Hormonal therapy count prior regimen ( either cytotoxic noncytotoxic ) . Any prior therapy direct malignant tumor , include chemotherapy immunologic agent , must discontinue least three week prior registration . Any prior radiation therapy must complete least 2 week prior registration . At least 4 week must elapse since patient underwent major surgery ( example , hysterectomy , resection metastatic nodule ) ; placement central venous catheter consider minor , major thus time minor procedure treatment study may shorter 4 week . Patients must least one prior chemotherapeutic regimen management leiomyosarcoma . Patients may one additional chemotherapeutic regimen management leiomyosarcoma , total two prior line therapy . Patients must NOT receive noncytotoxic ( biologic target ) agent part primary treatment management recurrent persistent disease . ( Patients previously treat GOG 0250 , randomize trial gemcitabinedocetaxel plus bevacizumab placebo , eligible , provided patient know treat placebocontaining arm receive prior bevacizumab ) Absolute neutrophil count ( ANC ) great equal 1,500/mcl ( 1.5 x 109/L ) . Platelets great equal 100,000/mcl ( 100 x 109/L ) . Hemoglobin great equal 9 g/dL . Patients may blood transfusion platelet transfusion within 7 day screen assessment . Creatinine le equal 1.5 mg/dL ( 133 umol/L ) , &gt; 1.5 mg/dl , calculate creatinine clearance must great equal 30 mL/min . Hepatic function : Bilirubin le equal 1.5 x ULN ( subject Gilbert 's syndrome elevation indirect bilirubin eligible ) . AST ALT less equal 2.5 x ULN alkaline phosphatase less equal 2.5 x ULN . Subjects BOTH bilirubin great ULN AST/ALT great ULN eligible . ( Specifically , bilirubin great 1 x ULN le equal 1.5 x ULN , THEN AST ALT must less equal ULN patient eligible . If AST /or ALT great 1 x ULN le equal 2.5 x ULN , THEN bilirubin must less equal ULN patient eligible . ) Urine Protein/ Creatinine Ratio ( UPCR ) must less 1 ( urinary protein le 1 g/24 hour ) . Blood coagulation parameter : PT international normalize ratio ( INR ) less equal 1.2 x ULN ( Patients anticoagulant therapy eligible INR stable , inrange INR , usually 2 3 ) PTT le equal 1.2 x ULN . Patients must sign approve informed consent authorization permit release personal health information . Patients meet preentry requirement specify section 7.0 . Patients childbearing potential must negative serum pregnancy test prior study entry practice effective form contraception . Patients must 18 year old . Patients must capable take absorb oral medication . Any concomitant medication associate risk QTc prolongation and/or Torsades de Pointes discontinue replace drug carry risk , possible . Patients must take medication risk possible risk Torsades de Pointes watch carefully symptoms QTc prolongation , syncope . See Appendix III list concomitant medication associate QTc Torsades de Pointes . Patients personal family history congenital long QTc syndrome NOT eligible . CYP3A4 Inhibitors : Strong inhibitor CYP3A4 prohibit . Grapefruit juice also inhibitor CYP450 take pazopanib . CYP3A4 Inducers : Strong inducer CYP3A4 prohibit . CYP Substrates : Concomitant use agent narrow therapeutic window metabolize CYP3A4 , CYP2D6 , CYP2C8 recommend . Prior therapy pazopanib . Patients invasive malignancy , exception nonmelanoma skin cancer , specific malignancy note Sections 3.23 3.24 , exclude evidence malignancy present within last three year . Patients also exclude previous cancer treatment contraindicate protocol therapy . Patients receive prior radiotherapy portion abdominal cavity pelvis OTHER THAN treatment uterine leiomyosarcoma within last three year exclude . Prior radiation localize cancer breast , head neck , skin permit , provide complete three year prior registration , patient remain free recurrent metastatic disease . Patients receive prior chemotherapy abdominal pelvic tumor OTHER THAN treatment uterine leiomyosarcoma within last three year exclude . Patients may receive prior adjuvant chemotherapy localize breast cancer , provide complete three year prior registration , patient remain free recurrent metastatic disease . Patient treat investigational agent device within 30 day enter study . Patient known history active Hepatitis B C. Patients clinically significant cardiovascular disease . This include : Patients must blood pressure ( BP ) great 140 mmHg ( systolic ) 90 mmHg ( diastolic ) eligibility . ( Note : initiation antihypertensive medication permit prior study entry . At least 24 hour must elapse antihypertensive medication initiation BP measurement . At time BP measure 3 time , approximately 2 minute apart , 3 value average . This average mean BP must less 140/90 mmHg . Myocardial infarction unstable angina cardiac angioplasty cardiac stenting coronary artery bypass graft surgery symptomatic peripheral vascular disease within 6 month first date pazopanib therapy . New York Heart Association ( NYHA ) Class II great congestive heart failure ( Appendix II ) . Women receive prior anthracycline ( e.g. , doxorubicin and/or liposomal doxorubicin ) ejection fraction less institutional low limit normal exclude study . Patients prior life time exposure doxorubicin ( liposomal doxorubicin ) great 300 mg/m2 NOT eligible . CTCAE grade 2 great peripheral vascular disease . History cerebrovascular accident ( CVA , stroke ) , transient ischemic attack ( TIA ) subarachnoid hemorrhage within six month first date pazopanib therapy . Women baseline QTc &gt; 480 millisecond . History cerebrovascular accident , include transient ischemic attack , pulmonary embolism , within past 6 month . ( Note : subject recent DVT ( PE ) treat therapeutic anticoagulation least six week eligible ) . A patient arterial thrombosis within 6 month prior enrollment . Patients history evidence upon physical examination CNS disease , include primary brain tumor , seizures control standard medical therapy brain metastasis . Active bleed pathologic condition carry high risk bleeding , know bleed disorder , coagulopathy , tumor involve major vessel . Serious , nonhealing wound , ulcer , bone fracture . This include history abdominal fistula , gastrointestinal perforation intraabdominal abscess within 28 day prior first date pazopanib therapy . Patients underlying lesion cause fistula perforation past correct . History allergic reaction attribute compound similar chemical biologic composition pazopanib . HIVpositive subject combination antiretroviral therapy ineligible potential pharmacokinetic interaction pazopanib . In addition , subject increase risk lethal infection treat marrowsuppressive therapy . Appropriate study undertaken subject receive combination antiretroviral therapy indicate . Patients pregnant nursing . Patients lactate discontinue nursing prior first dose study drug refrain nursing throughout treatment period 14 day follow last dose study drug . Patients condition may increase risk gastrointestinal bleed gastrointestinal perforation , include limited : active peptic ulcer disease know gastrointestinal intraluminal metastatic lesion risk bleeding ( gastrointestinal serosa metastatic lesion permit ) inflammatory bowel disease ( e.g. , ulcerative colitis , Crohn 's disease ) gastrointestinal condition increase risk perforation history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior begin study treatment History hemoptysis excess 2.5 mL ( 1/2 teaspoon ) within 8 week prior first dose pazopanib . Uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement . Major surgery trauma within 28 day prior first dose pazopanib . ( procedure catheter placement central venous access device placement consider major surgery ) Patients known endobronchial lesion and/or lesion infiltrate major pulmonary vessel increase risk pulmonary hemorrhage . ( Note , presence tumor touch infiltrate acceptable ; large protrude endobronchial lesion main lobar bronchus exclude ; lesion extensively infiltrate main lobar bronchus exclude ) Patients unwilling unable discontinue use prohibit medication least 14 day prior first dose study drug duration study ( see APPENDIX III regard concomitant medication section title `` prohibited medication '' ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>